Agenus Past Earnings Performance

Past criteria checks 0/6

Agenus's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 4.6% per year.

Key information

-14.5%

Earnings growth rate

12.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate4.6%
Return on equityn/a
Net Margin-142.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Agenus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:AJ8 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24160-228720
30 Jun 24160-224740
31 Mar 24161-240770
31 Dec 23156-246790
30 Sep 23101-271830
30 Jun 2399-263820
31 Mar 2395-240800
31 Dec 2298-220810
30 Sep 2290-215780
30 Jun 2232018810
31 Mar 22310-19790
31 Dec 21296-24760
30 Sep 213074740
30 Jun 2169-226670
31 Mar 2185-190650
31 Dec 2088-181590
30 Sep 2091-174520
30 Jun 2097-168490
31 Mar 2085-171460
31 Dec 19150-108460
30 Sep 19122-126430
30 Jun 19115-113410
31 Mar 19115-87390
31 Dec 1837-160370
30 Sep 1839-147370
30 Jun 1829-151360
31 Mar 1818-158350
31 Dec 1743-121340
30 Sep 1740-112330
30 Jun 1741-116330
31 Mar 1744-113320
31 Dec 1623-127330
30 Sep 1625-117330
30 Jun 1627-89310
31 Mar 1627-101320
31 Dec 1525-88280
30 Sep 1519-98250
30 Jun 1514-93230
31 Mar 1510-61220
31 Dec 147-43210
30 Sep 146-22200
30 Jun 145-22180
31 Mar 143-25170
31 Dec 133-33140

Quality Earnings: AJ8 is currently unprofitable.

Growing Profit Margin: AJ8 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AJ8 is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare AJ8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AJ8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: AJ8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agenus Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Robert WassermanDawson James Securities